FDA approves Emmaus’ Endari for sickle-cell disease: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm566084.htm Emmaus Life Sciences is private; it backed out of the reverse merger with GNBT announced in Jan 2017 (#msg-128148160).